TOLECINE™:

Tolecine™ is a pre-clinical LCP which has demonstrated safety and efficacy in vitro and in vivo. Conceived and synthesized initially at Kent State University, Tolecine regulates gene transcription factor NFkB. The compound is produced at the commercial scale by Materia-Inc of Pasadena, CA using a state-of-the-art metathesis platform developed at Caltech. (Grubbs et al, Noble Prize for Chemistry, 2005). Tolecine is under development for treatment of solid tumors and herpes virus. Animal data suggest Tolecine may be safer and ten times more effective than the guanine analog antiviral pro-drug valacyclovir. Tolecine is tumor cell selective and exhibits strong anti-neoplastic activity.